Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications
Randall W. Moreadith(The University of Texas Southwestern Medical Center), Warren Olanow(Mount Sinai Medical Center), Michael D. Bentley(Minnesota State University, Mankato), Kunsang Yoon, Bekir Dizman, J. Milton Harris(University of Alabama in Huntsville), Christoph Rader(Scripps Research Institute), Rebecca Weimer, Xiuling Li(Scripps Research Institute), Brendan P. Rae(Mirna Therapeutics (United States)), David G. Standaert(University of Alabama at Birmingham), Tacey X. Viegas(Mirna Therapeutics (United States)), Zhihao Fang(Xi'an University of Architecture and Technology)
Cited by 175
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration
|Journal of Neuroscience|2013|424
Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery
|Bioconjugate Chemistry|2011|424